78-LB: Efficacy and Safety of Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Compared with Insulin Degludec in Patients with Type 2 Diabetes (SURPASS-3)

Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 78-LB
Author(s):  
BERNHARD LUDVIK ◽  
FRANCESCO GIORGINO ◽  
ESTEBAN JODAR ◽  
JUAN PABLO FRIAS ◽  
LAURA FERNANDEZ LANDO ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Receptor Agonist ◽  
Insulin Degludec ◽  
Efficacy And Safety

scholarly journals Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial

Diabetes Care ◽  
2017 ◽  
Vol 41 (2) ◽  
pp. 333-340 ◽  
Author(s):  
Julio Rosenstock ◽  
John B. Buse ◽  
Rehan Azeem ◽  
Prakash Prabhakar ◽  
Lise Kjems ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Receptor Agonist ◽  
Efficacy And Safety ◽  
Oral Antidiabetes Drugs ◽  
Novel Drug

100-OR: ADA Presidents’ Select Abstract: Efficacy and Safety of Once-Weekly Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist vs. Placebo as Monotherapy in People with Type 2 Diabetes (SURPASS-1)

Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 100-OR
Author(s):  
JULIO ROSENSTOCK ◽  
CAROL H. WYSHAM ◽  
JUAN P. FRIAS ◽  
SHIZUKA KANEKO ◽  
CLARE LEE ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Receptor Agonist ◽  
Efficacy And Safety ◽  
Select Abstract
Sign in / Sign up

Export Citation Format

Share Document